Ionis Pharmaceuticals (IONS) EBITDA Margin (2009 - 2026)
Ionis Pharmaceuticals (IONS) recorded quarterly EBITDA Margin of 47.72% in Q1 2026, up 54.76% quarter-over-quarter from 105.47% in Q4 2025, and up 6387.0% on a YoY basis from 0.74% in Q1 2025.
Ionis Pharmaceuticals (IONS) EBITDA Margin (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' EBITDA Margin history runs 18 years deep, the most recent figure standing at 47.72% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 6387.0% year-over-year to 47.72%; the TTM figure through Mar 2026 stood at 57.92% (up 794.0% YoY), while the FY2025 annual figure was 8.45%, up 525.0% from the prior year.
- EBITDA Margin was 47.72% for Q1 2026 at Ionis Pharmaceuticals, up from 105.47% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 6990.8% in Q2 2025 to a low of 136.95% in Q4 2022.
- Historically, EBITDA Margin has averaged 340.85% across 5 years, with a median of 63.92% in 2022.
- The sharpest annual moves came in 2022 and 2025: EBITDA Margin plunged 18709 bps in 2022, then soared 702014 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 136.95% in 2022, then soared by 99 bps to 1.89% in 2023, then sank by 2493 bps to 48.91% in 2024, then slumped by 116 bps to 105.47% in 2025, then jumped by 55 bps to 47.72% in 2026.
- The last three EBITDA Margin figures came in at 47.72% (Q1 2026), 105.47% (Q4 2025), and 102.21% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ionis Pharmaceuticals | 12.23 Bn | 10.31 Bn | 243.11 Mn | -47.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.72% |
| Dec 31, 2025 | -105.47% |
| Sep 30, 2025 | -102.21% |
| Jun 30, 2025 | 6,990.80% |
| Mar 31, 2025 | -111.59% |
| Dec 31, 2024 | -48.91% |
| Sep 30, 2024 | -111.09% |
| Jun 30, 2024 | -29.34% |
| Mar 31, 2024 | -125.12% |
| Dec 31, 2023 | -1.89% |
| Sep 30, 2023 | -99.35% |
| Jun 30, 2023 | -47.87% |
| Mar 31, 2023 | -87.45% |
| Dec 31, 2022 | -136.95% |
| Sep 30, 2022 | -37.03% |
| Jun 30, 2022 | -63.92% |
| Mar 31, 2022 | -40.52% |
| Dec 31, 2021 | 50.14% |
| Sep 30, 2021 | -64.50% |
| Jun 30, 2021 | -58.03% |